Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of HeXell-2020 Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome

Authors not listed

Hexun Biosciences Co., LTD. · 2026

Stem-cell exhaustion Stem-cell therapy Human Randomized controlled trial

Abstract

This is a phase I study to investigate the safety, and Tolerability of HeXell-2020 in Elderly Subjects with Mild to Moderate Frailty Syndrome. HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-12 MST

Cite this

APA

Anonymous. (2026). A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of HeXell-2020 Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome. <em>Hexun Biosciences Co., LTD.</em>. https://clinicaltrials.gov/study/NCT07144072

Vancouver

Anonymous. A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of HeXell-2020 Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome. Hexun Biosciences Co., LTD.. 2026.

BibTeX

@misc{anon2026APhase, title = {A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of HeXell-2020 Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome}, author = {Anonymous}, journal = {Hexun Biosciences Co., LTD.}, year = {2026}, }